Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtend

por Deal, Chad L., Mitlak, Bruce H., Wang, Yamei, Fitzpatrick, Lorraine A., Miller, Paul D.
Publicado 2019

Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis

por Dempster, David W, Zhou, Hua, Rao, Sudhaker D, Recknor, Chris, Miller, Paul D, Leder, Benjamin Z, Annett, Miriam, Ominsky, Michael S, Mitlak, Bruce H
Publicado 2021

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data

por Cuzick, Jack, Sestak, Ivana, Bonanni, Bernardo, Costantino, Joseph P, Cummings, Steve, DeCensi, Andrea, Dowsett, Mitch, Forbes, John F, Ford, Leslie, LaCroix, Andrea Z, Mershon, John, Mitlak, Bruce H, Powles, Trevor, Veronesi, Umberto, Vogel, Victor, Wickerham, D Lawrence
Publicado 2013

Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia

por Reginster, Jean-Yves, Cooper, Cyrus, Rizzoli, René, Kanis, John A., Appelboom, Geoff, Bautmans, Ivan, Bischoff-Ferrari, Heike A., Boers, Maarten, Brandi, Maria Luisa, Bruyère, Olivier, Cherubini, Antonio, Flamion, Bruno, Fielding, Roger A., Gasparik, Andrea Ildiko, Van Loon, Luc, McCloskey, Eugene, Mitlak, Bruce H., Pilotto, Alberto, Reiter-Niesert, Suzanne, Rolland, Yves, Tsouderos, Yannis, Visser, Marjolein, Cruz-Jentoft, Alfonso J.
Publicado 2015